Jubilant Pharmova Limited — Financials & Forensics
Sector: Healthcare · NSE: JUBLPHARMA · BSE: 530019 · ISIN: INE700A01033
18 Aug 2026
Add JUBLPHARMA to your watchlist — all of this, automated.
Sign in with GoogleAnnual P&L snapshot
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue from operations | ₹6,059 Cr | ₹6,282 Cr | ₹6,703 Cr | ₹7,234 Cr | ₹8,280 Cr |
| EBITDA | ₹1,085 Cr | ₹776 Cr | ₹901 Cr | ₹1,174 Cr | ₹1,260 Cr |
| EBITDA margin | 17.9% | 12.4% | 13.4% | 16.2% | 15.2% |
| Profit after tax | ₹414 Cr | ₹-61 Cr | ₹77 Cr | ₹839 Cr | ₹398 Cr |
Deeper analysis
Recent filings by Jubilant Pharmova Limited
-
Press Release and presentation
10 Aug 2026 · Financial Results
-
outcome of Board meeting
10 Aug 2026 · Financial Results
Never miss a filing again
About Jubilant Pharmova Limited on Indian Stock Alerts
Indian Stock Alerts tracks Jubilant Pharmova Limited's SEBI / exchange filings in real time. Every quarterly result, audited annual report, shareholding pattern update, insider trade and corporate announcement is automatically parsed and surfaced as a structured data point — with a link back to the underlying filing.
Data points refreshed daily include closing price, 1Y change, market cap, P/E, ROE, dividend yield, RPT volume, audit / governance / accrual flags. Quarterly results numbers refresh within minutes of the company filing them with BSE / NSE.